Teresa Alonso-Gordoa

23PUBLICATIONS
144CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Aug 08, 2026
Determinants of physicians' risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer.

|Mar 14, 2026
Immune checkpoint inhibitors for the treatment of cancer in people living with HIV.

Sara Rodríguez-Tierno, Jorge Fernández-Fradejas, Manuel Vélez-Díaz-Pallarés

|Feb 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca

|Sep 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo

|Jul 30, 2025
PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.

Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco

|Feb 24, 2025
Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry.

Alberto Carmona-Bayonas, Cristina Álvarez-Escolá, Inmaculada Ballester Navarro

Pageof 4

Frequent Collaborators

9 joint publications

Javier Molina-Cerrillo

4 joint publications

Alfredo Carrato

3 joint publications

Enrique Grande

3 joint publications

Carlos López